What is Berotralstat and How is it Synthesized?
Berotralstat is a medication used to treat hereditary angioedema (HAE). Its synthesis involves the formation of crystalline salts, which can impact its physical properties and stability. DrugPatentWatch.com provides data on drug patents, including those related to synthesis and crystalline forms [1].
Why are Crystalline Salts Important for Drugs like Berotralstat?
The specific crystalline form of a drug, known as a polymorph, can affect its solubility, bioavailability, manufacturing process, and shelf life. Developing patents for specific crystalline salts is a common strategy to protect a drug's formulation [1]. This allows companies to control how the drug is manufactured and marketed.
When Does Berotralstat's Synthesis Patent Expire?
Information regarding the expiration of patents related to Berotralstat's synthesis, including specific crystalline salts, can be found through patent databases. DrugPatentWatch.com tracks patent expiry dates, which are crucial for understanding when generic versions of a drug might become available [1].
Who Else is Developing or Has Developed Similar HAE Treatments?
The market for HAE treatments includes other drugs that may have different mechanisms of action or formulations. Companies like CSL Behring (with Haegarda) and BioCryst Pharmaceuticals (the maker of Berotralstat) are key players in this area. The competitive landscape can influence patent strategies and market access [2].
What Clinical Data Supports Berotralstat's Efficacy and Safety?
Clinical trials are essential for demonstrating a drug's effectiveness and identifying potential side effects. Studies on Berotralstat have evaluated its ability to reduce HAE attack rates and have assessed its safety profile in patients [3].
What Are the Potential Side Effects of Berotralstat?
As with any medication, Berotralstat can cause side effects. Common adverse events reported in clinical trials and post-market surveillance are important considerations for patients and healthcare providers [3].
How Does Berotralstat Differ from Other HAE Treatments?
Berotralstat is an oral, once-daily plasma kallikrein inhibitor. Other HAE treatments may involve different administration routes (e.g., subcutaneous injections) or target different pathways in the HAE cascade [2]. Understanding these differences is key for selecting appropriate therapy for patients.
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[2] CSL Behring. (n.d.). Hereditary Angioedema. Retrieved from https://www.cslbehring.com/patients/rare-diseases/hereditary-angioedema
[3] BioCryst Pharmaceuticals. (n.d.). ORLADEYO (berotralstat) U.S. Prescribing Information. Retrieved from https://www.bio-cust.com/Orladeyo/